Nicotine for COVID-19: real-time analysis

Download Image

Post

c19early.org

Nicotine for COVID-19

1 study with 213 patients

Serious outcome risk

Nicotine

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Nicotine studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−5%

Mortality (1)−5%

RCTs (1)−5%

Late (1)−5%

00.511.5+

← Nicotine
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Jun 9 2022	Labro et al., Intensive Care Medicine, doi:10.1007/s00134-022-06721-1	Nicotine patches in patients on mechanical ventilation for severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial
Jun 9 2022	5% higher mortality (p=0.78) and 6% higher progression (p=1). RCT 218 critically ill COVID-19 patients showing no benefit of transdermal nicotine patches. The trial tested a hypothesis that emerged early in the pandemic based on observations of lower COVID-19 rates among smokers, however alternative..